PPARA and post-traumatic stress disorder: Progress in assessing biomarkers to predict PTSD and its treatment response will guide the future of novel PTSD medications that may be designed to improve neurotransmission (GABA, NMDA), and neuroendocrinologic (allopregnanolone biosynthesis) and anti-inflammatory (PPAR-α) responses.